Eight Months After First FDA Approval, Aurinia Picks Up Two More Candidates

After the historic approval of their first-ever drug in January, Aurinia Pharmaceuticals was out looking for what's next for their company. Today the Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.